Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement slow MS brain damage? new trial seeks answers.

NCT ID NCT05122559

Disease control Sponsor: Emmanuelle Waubant, MD PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether N-acetyl cysteine (NAC), a supplement, can protect the brain in people with progressive multiple sclerosis (MS). About 98 adults with primary or secondary progressive MS will receive either NAC or a placebo for 15 months. Researchers will measure brain shrinkage on MRI scans and check safety and thinking abilities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 98 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- 40-70 (inclusive) years in age, * meet 2017 McDonald criteria (Thompson 2018), * patients with primary or secondary progressive MS (Thompson 2018), * at least 2 years since progressive symptom onset, * evidence of clinical changes over the previous 2 years unrelated to relapses: increased EDSS or 20% slowing on 25-foot walk, change of ambulatory support, cognitive change documented on cognitive testing. Progression defined by patients in terms of ambulation perimeter or type of support to ambulate are acceptable if aforementioned physician-based measure changes are not available. * EDSS score 3.0 to 7.0 (inclusive), * can be on a stable disease-modifying treatment initiated \> 3 months prior to screening, * can be on stable doses of dalfampridine initiated at least one month before screening. Exclusion Criteria: * \- MS relapses in the previous 6 months * oral glucocorticosteroid treatment within the prior 3 months * patient with issues undergoing MRI scans * pregnancy or breastfeeding * women of child-bearing potential not able to utilize an effective form of contraception for the duration of the study * history of bleeding disorders * active gastrointestinal ulcers * abnormal liver function testing (aminotransferase (AST) or alanine aminotransferase (ALT) \>2 times upper limit of normal) * current treatment for active malignancy or metastatic malignancy treated in the past year * alcohol or substance use disorder * allergy to NAC * planned surgery or move within 15 months * use of medications/supplements with antioxidant properties (including over-the-counter NAC)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis primary progressive multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis Multiple sclerosis, primary progressive Multiple sclerosis, secondary progressive

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.